Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,582,212 shares of the company’s stock after buying an additional 3,896,790 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 7.1% of Migdal Insurance & Financial Holdings Ltd.’s investment portfolio, making the stock its biggest position. Migdal Insurance & Financial Holdings Ltd. owned about 2.84% of Teva Pharmaceutical Industries worth $658,161,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in TEVA. Bourgeon Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock worth $12,134,000 after acquiring an additional 363,252 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after purchasing an additional 37,455 shares during the period. Oak Harvest Investment Services purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $1,010,000. Swiss National Bank grew its stake in shares of Teva Pharmaceutical Industries by 15.5% in the second quarter. Swiss National Bank now owns 3,616,500 shares of the company’s stock worth $60,613,000 after purchasing an additional 486,100 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 in the last ninety days. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, December 22nd. Scotiabank assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective on the stock. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Jefferies Financial Group boosted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $31.38 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $33.42. The company has a market capitalization of $35.99 billion, a price-to-earnings ratio of 52.30, a PEG ratio of 1.82 and a beta of 0.66. The firm’s 50-day moving average is $29.27 and its 200 day moving average is $22.35. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.